Home
NewsNewsUNC Fertility has announced its plans for Collaboration with IVI RMA North America to bring best clinical and operational best practices across the region, expanding access to cutting-edge fertility treatments and research.
One of North Carolina’s leading providers when it comes to fertility treatment and care, UNC Fertility, on February 11, 2026, went ahead and announced its plans to expand to accommodate the growing demand from the growing population of the state and form a new collaboration with IVI RMA North America, which is one of the leading providers in terms of reproductive medicine services in the country.
The Raleigh location of the clinic has gone on to hire many new providers and is also looking to accommodate plans to open some more locations all across the state in a matter of time. The collaboration with IVI RMA North America will bring clinical and operational best practices for patient service in the Triangle and the surrounding region. IVI RMA Global, which is the parent company, goes on to offer reproductive medicine services in 15 countries with over 200 locations.
UNC Health’s Division Chief of Reproductive Endocrinology and Infertility and Medical Director at UNC Fertility, Dr. Colleen Milroy, said that “UNC Fertility is proud to serve the more than 2.4 million residents of the Triangle. Our region is one of the fastest growing in the country, and its population deserves the best patient care. This partnership with IVI RMA will ensure UNC Fertility is well-positioned to scale access over time, adding more providers and locations and broadening the types of treatments available to meet the demands from our diverse and expanding population.”
Apparently, UNC Health is going to retain complete ownership of the UNC Fertility practice, with all the physicians and care providers to remain employees of UNC Health. The present patients of UNC Fertility are going to continue to see their already local, dedicated providers.
Moreover, IVI RMA, along with UNC Health, is going to work together to create new opportunities as far as joint research and education programs are concerned. As part of the agreement, IVI RMA is going to partner with UNC Fertility when it comes to UNC Reproductive Endocrinology and the Infertility Fellowship so as to prepare a diverse group of physicians and hence become reproductive endocrinology and infertility service leaders. It is well to be noted that IVI RMA brings in valuable experience due to its present partnership with fellowship programs from Harvard University School of Medicine as well as Thomas Jefferson University.
According to the CEO of IVI RMA North America, Lynn Mason, “It’s an honor to partner with a globally recognized academic medical center like UNC Health and build on their already exceptional clinical foundation and outcomes. We’re excited to work with UNC Fertility as their team continues to grow their presence in North Carolina and the surrounding regions. This partnership reflects our shared dedication to advancing patient care and inspiring future leaders in reproductive endocrinology.”
ARMS Embryo Watch offers time-lapse images of IVF embryos to patients by streaming each development stage and showing the output directly to the patient's device, enhancing transparency and emotional connection throughout the IVF journey.
Mochida Grants LG Chem Endometriosis Drug Licensing to develop and sell Dinagest that has an active ingredient, Dienogest, that halts endometrial cells from growing, offering a non-hormonal therapeutic option for women suffering from endometriosis.
Luna and Kindbody are redefining Intelligence in Fertility Care through a strategic partnership that integrates wearable biomarker tracking into clinical pathways. By capturing real-time physiological data, the collaboration enables personalised insights, enhances decision-making, and creates a more connected, data-driven fertility journey for patients and care providers alike.
The MOAA-Endorsed Bill for Fertility Challenges seeks to expand fertility care access for veterans by recognising infertility as a service-connected condition. By reducing barriers to IVF and treatment, the legislation addresses toxic exposure risks and aims to provide timely, equitable reproductive healthcare support for those who served.
Fairfax IVI expand donor sperm access through a strategic partnership that enhances availability, integrates donor services into fertility care, and supports diverse patient needs. With personalised guidance, genetic insights, and streamlined logistics, the collaboration aims to reduce barriers and deliver a more accessible, inclusive path to parenthood.
Sapyen and Avenues launch at-home fertility diagnostics, introducing a couple-first testing model in the UK. By integrating semen analysis and AMH testing into early care, this approach reduces clinic visits, accelerates diagnosis, and ensures balanced fertility evaluation, transforming how patients begin their reproductive health journey.
Nexpring Health has invested in May Health to accelerate the development of the Anavi™ System, a novel device designed to treat PCOS-Related Infertility. The technology aims to restore ovulation through a single office-based procedure, expanding treatment options for millions of women affected by polycystic ovary syndrome.
